The presence of AML1-ETO (RUNX1-CBF2T1), a fusion oncoprotein resulting from a t(8;21) chromosomal translocation, is a necessary but insufficient event in the development of a subset of acute myeloid leukemias (AML). Although AML1-ETO is able to block differentiation and immortalize hematopoietic stem cells, other contributory events are required for cell proliferation and leukemogenesis, suggesting that specific tumor suppressor genes may counteract the leukemic potential of AML1-ETO. In studying del(9q), one of the most common concomitant chromosomal abnormalities with t(8;21), we identified the loss of TLE4 as a key cooperating event in the development of AML1-ETO AML, leading to increased cell proliferation, blocked apoptosis and differentiation, as well as cytarabine resistance in leukemic cells. This suggested TLE4 functions as a tumor suppressor gene in AML.We found these effects are mediated by the loss of TLE4 regulation of a COX-Wnt inflammatory axis. These effects were consequently reversible by Wnt signaling and cyclooxygenase inhibition, pointing towards anti-inflammatory agents as potentially new therapeutic and adjuvant strategies for AML. While studies in Drosophila implicate TLE/Groucho as a key mediator of various signaling pathways, including receptor tyrosine kinase/Ras/MAPK, Notch, Myc, and Wnt pathways, there is surprisingly little known about the role of TLE in mammalian development. Using a Tle4 knockout (T4KO) mouse, we identified previously unknown roles for Tle4 in regulating vertebrate mammalian hematopoietic and bone development. T4KO mice manifest leukocytopenia and defective hematopoietic stem cell populations. Using serial transplantation and stromal co-culture, we find that these hematopoietic deficiencies arise due to both intrinsic dysfunction of hematopoietic stem cells as well as defective extrinsic regulation of hematopoiesis by the stem cell niche. Additionally, T4KO mice are severely runted and exhibit markedly decreased bone mineralization concomitant with defective osteoblast function and decreased mineral apposition rates. Many of the pathways regulated by TLE are aberrant in cancer, which has led to increasing studies connecting TLE with various malignancies, including synovial cell sarcoma and glioblastoma. Our findings have great implications for current understanding of TLE function in not only cancer, but also bone and hematopoietic development.

It is widely accepted that activating mutations of genes encoding the Notch family of transmembrane receptors, specifically Notch1, are associated with oncogenic transformation. Previous data from our lab has shown that an active form of Notch1 (NICD) provides protection against apoptosis in D011.10 T cells; and that this effect may be attributed to NICD binding the pro-apoptotic protein Nur77. Nur77 is an immediate early gene that is upregulated during both negative selection of thymocytes and activation-induced apoptosis in D011.10 T cells. Nur77 upregulation is tightly regulated and requires MEF2D, NFAT, and the transcriptional co-activator, p300, to effectively respond to apoptotic stimuli. Here, we show that NICD has the ability to interfere with the transcription of Nur77, and that this interference is directly related to the inability of p300 to bind the Nur77 promoter in the presence of NICD. We also show that blocking Notch activation, through inhibition of gamma secretase or shRNA directed against Notch1, in T cell acute lymphoblastic leukemia (T-ALL) cell lines restores Nur77 expression in response to apoptotic stimuli. These observations support a mechanism by which NICD over-expression can suppress the activation of a known pro-apoptotic molecule, and further suggests this mechanism may operate in T-ALL.

No description available.

In patients with acute myeloid leukemia (AML), cytarabine-based chemotherapy usually achieves remission, but this is commonly followed by relapse and chemo-resistance. In this study, we aim to establish next-generation sequencing (NGS)-based microRNA expression profiling and pathway analysis to identify pathways regulated differentially between chemo-sensitive and -resistant AML as potential therapeutic targets. MicroRNA expression profiles differ significantly between chemo-sensitive and chemo-resistant AML cells and reflect differences in the activity of intracellular signaling cascades. Alterations in signaling pathway activities contribute to treatment resistance and thus represent potential drug targets. Our microRNA-led approach indicates a role for activin receptor type 2A in ARA-C resistance of AML cells and suggests activin receptor signaling to be a candidate pathway for targeted therapy.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.